Form 4: Tela Bio Director Lisa Colleran Reports Acquisition and Disposal of Common Stock and Stock Options

Director Lisa Colleran reported acquiring 4,250 shares of common stock and 6,200 stock options, while disposing of 10,520 shares of common stock.

Summary

• On June 4, 2024, Lisa Colleran, a director of Tela Bio, Inc., reported transactions involving the company's securities.
• Colleran acquired 4,250 shares of common stock at $0 and disposed of 10,520 shares of common stock.
• She also acquired 6,200 stock options with an exercise price of $5.71, exercisable on the earlier of June 4, 2025, the next annual meeting of stockholders, or a Change in Control, expiring on June 4, 2034.
• Following these transactions, Colleran beneficially owns 10,520 shares of common stock and 6,200 stock options.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing represents routine transactions by a company director. The acquisition of options could be seen as slightly positive, while the disposal of shares could be seen as slightly negative. Overall, it's a balanced view.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Negatives

• The disposal of 10,520 shares of common stock by a director could be interpreted negatively by investors.

Risks

• The vesting of restricted stock units and stock options is contingent upon continued service and could be forfeited if the Reporting Person's service terminates before the vesting date.
• A 'Change in Control' event, as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan, could trigger vesting, which may or may not be beneficial to the company's long-term strategy.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to monitor the actions of those with privileged information.

Key Dates